New drug trial aims to boost lung power in deadly hypertension
NCT ID NCT07140484
Summary
This study is testing whether a medication called sotatercept can improve how well the lungs absorb oxygen during exercise in people with pulmonary arterial hypertension (PAH). Twenty-seven adult participants who are already on stable PAH medications will receive sotatercept injections every three weeks for 29 weeks. Researchers will measure lung function, exercise capacity, and heart health through multiple clinic visits to see if the drug helps recruit more blood vessels in the lungs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Physiology Laboratory
RECRUITINGEdmonton, Alberta, T6G2R3, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.